The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for ...

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection By Mabwell Jun 27, 2025 Updated Jun 27, 2025 ...

Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA.

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for InjectionSHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative ...

Kobalt partners with Chordal to streamline global sync licensing — the first time it has relied on a third-party platform to power sync transactions.

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market ...